Shares of G1 Therapeutics took a major hit, falling 46% to $2.44 in after-hours trading on Monday, following an update on its Phase 3 trilaciclib combination trial.
Trial Continuation Recommended by Data Monitoring Committee
The independent Data Monitoring Committee has recommended the continuation of the trial assessing the effectiveness of trilaciclib in combination with gemcitabine and carboplatin for the first-line treatment of metastatic triple-negative breast cancer. The final analysis of the trial is expected to take place in the third quarter.
Remaining Blind to Data
G1 Therapeutics has stated that it remains blind to all data as the interim analysis did not meet the criteria for early stopping. However, the company is eager to complete the study and potentially offer this new treatment option to patients by next year.
Safety Concerns Addressed
The committee expressed no concerns regarding the safety of the trial or proposed any changes to the study.
About Trilaciclib
Trilaciclib, also known as Cosela, was launched in 2021 and has been approved by the Food and Drug Administration as a therapy to reduce chemotherapy-induced bone marrow suppression in adults undergoing certain types of chemotherapy treatment.
